NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT01856283 2021-01-13
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
Niguarda Hospital
Phase 2 Completed
NCT04015024 2019-07-16
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown